Research Article
Prevalence and Clinical Characteristics including Patterns of Antihypertensive Drug Administration of the Different Home Blood Pressure Phenotypes in Treated Hypertensive Patients
Table 1
Baseline characteristics of home blood pressure phenotypes by using a home blood pressure target of <135/85 mmHg.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BMI, body mass index; kg/m2, kilogram/meter2; CVD, cardiovascular disease; MRA, mineralocorticoid receptor antagonist; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-II receptor blockers; DHP-CCBs, dihydropyridine calcium channel blockers; non-DHP-CCBs, nondihydropyridine calcium channel blockers; BBs, beta-blockers; FBS, fasting blood sugar; HbA1C, hemoglobin A1C; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; eGFR, estimated glomerular filtration rate; mg/g, a milligram of albuminuria/gram of urine creatinine; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; mmHg, millimeter of mercury. value for comparing parameters of all home blood pressure phenotypes. included a previous history of myocardial infarction, heart failure, ischemic stroke, or hemorrhagic stroke. † value <0.05 for comparing to controlled hypertension. ‡ value <0.05 for comparing to isolated uncontrolled morning hypertension. value <0.05 for comparing to isolated uncontrolled evening hypertension. |